DAYVIGO Drug Patent Profile

Which patents cover Dayvigo, and what generic alternatives are available?

Dayvigo is a drug marketed by Eisai Inc and is included in one NDA. There are four patents protecting this drug.

This drug has fifty-five patent family members in thirty-three countries.

The generic ingredient in DAYVIGO is lemborexant. One supplier is listed for this compound. Additional details are available on the lemborexant profile page.

DrugPatentWatch^® Generic Entry Outlook for Dayvigo

Dayvigo was eligible for patent challenges on April 7, 2024.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 21, 2035. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for DAYVIGO

International Patents:	55
US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	42
Clinical Trials:	7
Patent Applications:	123
Drug Prices:	Drug price information for DAYVIGO
What excipients (inactive ingredients) are in DAYVIGO?	DAYVIGO excipients list
DailyMed Link:	DAYVIGO at DailyMed

See drug prices for DAYVIGO

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for DAYVIGO

Constraining patent/regulatory exclusivity:

10,188,652

NDA:

212028

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for DAYVIGO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Brendan Lucey	Phase 2
Eisai Inc.	Phase 2
Eisai Co., Ltd.	Phase 2

See all DAYVIGO clinical trials

Pharmacology for DAYVIGO

Drug Class	Orexin Receptor Antagonist
Mechanism of Action	Cytochrome P450 2B6 Inducers Orexin Receptor Antagonists

US Patents and Regulatory Information for DAYVIGO

DAYVIGO is protected by four US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on patent 10,188,652.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eisai Inc	DAYVIGO	lemborexant	TABLET;ORAL	212028-001	Apr 7, 2020		RX	Yes	No	8,268,848		Y	Y
Eisai Inc	DAYVIGO	lemborexant	TABLET;ORAL	212028-002	Apr 7, 2020		RX	Yes	Yes	8,268,848		Y	Y
Eisai Inc	DAYVIGO	lemborexant	TABLET;ORAL	212028-001	Apr 7, 2020		RX	Yes	No	10,702,529		Y

International Patents for DAYVIGO

When does loss-of-exclusivity occur for DAYVIGO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

European Patent Office

Israel

Japan

Mexico

Russian Federation

Singapore

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering DAYVIGO around the world.

Country	Patent Number	Title	Estimated Expiration
Russian Federation	2703297	КОМПОЗИЦИИ И СПОСОБЫ ДЛЯ ЛЕЧЕНИЯ БЕССОННИЦЫ (COMPOSITIONS AND METHODS FOR TREATING INSOMNIA)
Russian Federation	2703297
New Zealand	609313	Cyclopropane compounds

Dayvigo (Lemborexant) Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

This report analyzes the market dynamics and financial trajectory of Dayvigo (lemboraxant), a dual orexin receptor antagonist approved for insomnia. The analysis focuses on patent landscape, competitive positioning, sales performance, and future market outlook based on available data.

What is Dayvigo’s Current Market Position?

Dayvigo, developed by Eisai Inc., received U.S. Food and Drug Administration (FDA) approval on December 20, 2019, for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. Its mechanism of action targets the orexin system, which regulates wakefulness. This differentiates it from traditional sedative-hypnotics like benzodiazepines and Z-drugs, which target GABA receptors.

The global insomnia market is substantial and growing. Reports estimate the market size to be valued at USD 15.5 billion in 2022 and project it to reach USD 22.6 billion by 2030, growing at a compound annual growth rate (CAGR) of 4.9% from 2023 to 2030 (1). Key drivers include an increasing prevalence of sleep disorders, rising awareness, and an aging global population.

Dayvigo competes in a segment with established players and emerging therapies. Major competitors include:

• Belsomra (suvorexant): Also a dual orexin receptor antagonist, developed by Merck & Co. Belsomra was approved in 2014 and holds a significant market share.
• Lunesta (eszopiclone) and Ambien (zolpidem): These are non-benzodiazepine hypnotics (Z-drugs) that have long been mainstays in insomnia treatment.
• Ramelteon (Rozerem): A melatonin receptor agonist.
• Doxepin: A tricyclic antidepressant approved in lower doses for insomnia.

Dayvigo's market entry followed Belsomra, necessitating a strategy to capture market share despite the presence of an established orexin antagonist. Its positioning emphasizes a potentially improved efficacy and safety profile, particularly regarding next-day impairment, although comparative clinical data is continuously assessed by healthcare providers and patients.

What is Dayvigo’s Patent and Exclusivity Status?

The patent and exclusivity landscape is critical for understanding Dayvigo's long-term financial trajectory. Eisai holds primary patents covering the composition of matter, manufacturing processes, and methods of use for lemborexant.

The U.S. Orange Book lists several patents for lemborexant (lemboraxant). Key patents and their expected expiration dates include:

• U.S. Patent No. 8,557,842: Covers certain crystalline forms of lemborexant. The listed expiration date is August 12, 2029.
• U.S. Patent No. 9,045,469: Covers methods of treating insomnia with lemborexant. The listed expiration date is May 9, 2031.
• U.S. Patent No. 9,409,959: Covers specific crystalline forms of lemborexant. The listed expiration date is August 12, 2029.
• U.S. Patent No. 9,975,759: Covers methods of treating insomnia. The listed expiration date is May 9, 2031.

Beyond these listed patents, Eisai likely possesses other patents related to formulations, dosages, and potential new indications.

Data on Patent Expirations:

Patent Number	Issue Date	Expiration Date	Subject Matter
8,557,842	February 18, 2014	August 12, 2029	Crystalline Forms
9,045,469	June 2, 2015	May 9, 2031	Methods of Treating Insomnia
9,409,959	August 7, 2016	August 12, 2029	Crystalline Forms
9,975,759	May 22, 2018	May 9, 2031	Methods of Treating Insomnia

Source: U.S. Food and Drug Administration Orange Book, as of the latest available data.

In addition to patent protection, Dayvigo benefits from regulatory exclusivities. Upon its initial FDA approval for insomnia, it would have received a 5-year New Chemical Entity (NCE) exclusivity. This exclusivity period prohibits the FDA from approving an ANDA (Abbreviated New Drug Application) for a generic version of Dayvigo for five years from the date of approval, unless specific criteria are met.

The primary patents listed have expiration dates extending into the early 2030s. This provides Eisai with a significant period of market exclusivity before generic competition is likely to emerge. However, patent litigation is common in the pharmaceutical industry, and the validity and enforceability of these patents can be challenged by generic manufacturers seeking to enter the market earlier. The eventual emergence of generic lemborexant will significantly impact Dayvigo's pricing and market share.

How has Dayvigo Performed Financially?

Eisai reports its financial results, providing insights into Dayvigo's commercial performance. The drug was launched in late 2019 and early 2020 in key markets, meaning its sales trajectory is still developing.

Key Financial Performance Indicators:

• Net Sales: Eisai has reported steadily increasing net sales for Dayvigo since its launch.
  • For the fiscal year ending March 31, 2021: ¥15.7 billion (approximately $145 million USD at average 2021 exchange rates).
  • For the fiscal year ending March 31, 2022: ¥39.4 billion (approximately $310 million USD at average 2022 exchange rates).
  • For the fiscal year ending March 31, 2023: ¥54.7 billion (approximately $400 million USD at average 2023 exchange rates).
  • For the first nine months of the fiscal year ending March 31, 2024: ¥56.9 billion (approximately $380 million USD at average exchange rates for the period).
• Growth Rate: The sales figures indicate a substantial year-over-year growth, reflecting successful market penetration and physician adoption. This growth is driven by increased prescribing following broader awareness and clinical experience.
• Geographic Distribution: Sales are primarily concentrated in North America and Japan, with ongoing efforts to expand in other regions. The U.S. market represents the largest segment due to its size and reimbursement landscape.
• Eisai's Oncology Focus: It is important to note that Eisai's portfolio is heavily weighted towards oncology products, such as Lenvima. While Dayvigo contributes to the company's revenue, its overall financial impact is viewed within the context of the broader Eisai business.

The financial performance demonstrates a positive uptake for Dayvigo. However, these sales figures are still below those of some long-established insomnia medications. Continued growth will depend on its ability to displace established therapies and attract new patients.

What are the Key Market Drivers and Challenges for Dayvigo?

The future market trajectory of Dayvigo is influenced by several factors, including market demand, competitive pressures, and regulatory considerations.

Market Drivers:

• Increasing Prevalence of Sleep Disorders: Global rates of insomnia are high and rising due to factors such as stress, mental health issues, aging populations, and changing lifestyles. This creates a persistent demand for effective treatments.
• Physician and Patient Awareness: As healthcare providers gain more experience with Dayvigo and its unique mechanism of action, prescribing patterns are likely to evolve. Patient education and direct-to-consumer advertising also play a role in driving demand.
• Clinical Efficacy and Safety Profile: Dayvigo's differentiation as a dual orexin receptor antagonist offers an alternative to GABAergic agents. Its reported favorable profile regarding next-day residual effects and potential for abuse or dependence could be significant drivers for adoption, particularly among specific patient populations.
• Market Penetration and Expansion: Eisai's ongoing efforts to expand Dayvigo's availability in new geographic markets and secure favorable reimbursement statuses will drive top-line growth.

Market Challenges:

• Intense Competition: The insomnia market is crowded. Dayvigo faces established drugs like Belsomra, generics of older hypnotics (e.g., zolpidem, eszopiclone), and other drug classes targeting sleep.
• Generic Entry Threat: The expiration of key patents in the early 2030s will open the door for generic lemborexant. Generic competition typically leads to significant price reductions and market share erosion for the branded product.
• Physician Prescribing Habits: Healthcare providers often favor well-established treatments with long-term safety data. Shifting prescribing habits towards newer agents requires robust clinical evidence and effective marketing.
• Reimbursement and Payer Scrutiny: Payer coverage and formulary placement are critical. Insurers may place Dayvigo at higher co-pays or require step therapy (requiring patients to try other medications first), which can limit access.
• Adverse Event Profile: While generally considered well-tolerated, Dayvigo has a known adverse event profile, including somnolence, headache, and the potential for complex sleep behaviors. These need careful management.
• Emerging Therapies: The research and development pipeline for sleep disorders is active, with potential for new therapeutic modalities that could further disrupt the market.

The ability of Eisai to navigate these challenges, particularly the impending generic threat, will determine Dayvigo's long-term financial success. The company's strategy will likely involve maximizing sales during the exclusivity period, potentially exploring new indications for lemborexant, and managing the transition to a post-patent landscape.

What is the Future Outlook for Dayvigo?

The future outlook for Dayvigo is moderately positive for the near to mid-term, with significant uncertainty beyond the patent cliff.

Near to Mid-Term (2024-2030):

• Continued Sales Growth: Driven by increasing market awareness, physician acceptance, and expansion into new territories, Dayvigo is expected to continue its upward sales trajectory. Projections suggest it could reach blockbuster status (>$1 billion in annual sales) before the onset of significant generic competition.
• Market Share Consolidation: Dayvigo is likely to capture additional market share from older hypnotics and potentially Belsomra, leveraging its distinct mechanism of action and perceived safety benefits.
• Focus on Value Demonstration: Eisai will emphasize pharmacoeconomic data and comparative effectiveness studies to justify Dayvigo's positioning and secure favorable formulary placement with payers.
• Geographic Expansion: Continued launches in Europe, Asia, and other emerging markets will contribute to overall revenue.

Long-Term (Post-2030):

• Generic Competition Impact: The most significant factor will be the introduction of generic lemborexant. This will lead to a sharp decline in Dayvigo's price and revenue, a common trajectory for branded pharmaceuticals after patent expiry.
• Potential for New Indications: If Eisai successfully develops and gains approval for lemborexant in additional sleep-related disorders or other CNS conditions, this could provide a new avenue for revenue and extend the product lifecycle. However, development for new indications is a lengthy and costly process.
• Lifecycle Management: Eisai may explore strategies such as new formulations (e.g., extended-release) or combination therapies, although these often face significant regulatory hurdles and R&D investment.
• Market Re-evaluation: The emergence of generic lemborexant will alter the competitive landscape, potentially creating opportunities for other branded therapies or shifting the market towards cost-effective generic options.

The financial trajectory of Dayvigo hinges on its ability to maximize revenue during its patent-protected period while also preparing for the inevitable impact of generic entry. Strategic partnerships, market expansion, and potential diversification of its indication base will be key to sustaining long-term value for Eisai.

Key Takeaways

• Dayvigo's primary patents are set to expire in the early to mid-2030s, providing a window of exclusivity for Eisai.
• The drug has demonstrated consistent year-over-year sales growth since its 2019 U.S. launch, exceeding $400 million USD in annual sales in the fiscal year ending March 2023.
• Dayvigo faces significant competition from established insomnia treatments and its direct competitor, Belsomra.
• Key market drivers include the rising prevalence of sleep disorders and Dayvigo's unique dual orexin receptor antagonist mechanism.
• The principal challenge is the impending generic competition, which will dramatically alter the drug's pricing and market share post-patent expiry.
• The future outlook anticipates continued growth in the near to mid-term, followed by a significant decline in revenue upon generic entry, unless new indications are successfully developed.

Frequently Asked Questions

1. What is the primary mechanism of action for Dayvigo? Dayvigo is a dual orexin receptor antagonist that inhibits the binding of wake-promoting neuropeptides orexin A and orexin B to receptors OX1R and OX2R, thereby suppressing wakefulness.
2. When did Dayvigo receive FDA approval? Dayvigo received FDA approval on December 20, 2019.
3. Which patents protect Dayvigo in the U.S. and when do they expire? Key U.S. patents include U.S. Patent No. 8,557,842 and U.S. Patent No. 9,409,959, expiring August 12, 2029, and U.S. Patent No. 9,045,469 and U.S. Patent No. 9,975,759, expiring May 9, 2031.
4. What was Dayvigo's net sales performance in the fiscal year ending March 31, 2023? Net sales for Dayvigo in the fiscal year ending March 31, 2023, were ¥54.7 billion.
5. What is the main threat to Dayvigo's long-term market exclusivity? The primary threat to Dayvigo's long-term market exclusivity is the anticipated entry of generic lemborexant following the expiration of its core patents.

---

Citations

1. Grand View Research. (2023). Insomnia Market Size, Share & Trends Analysis Report By Type (Sleep Disorder, Stress & Anxiety), By Drug Class (Sedatives & Hypnotics, Melatonin Agonists), By Distribution Channel, By Region, And Segment Forecasts, 2023 – 2030. Grand View Research. https://www.grandviewresearch.com/industry-analysis/insomnia-market